



## Shasun Pharmaceuticals Limited

3rd & 4th Floor, 'Batra Centre',  
28, Sardar Patel Road, Guindy,  
Chennai - 600032, Tamil Nadu, India.

### PRESS RELEASE

Chennai, 6<sup>th</sup> August 2014

#### Shasun Pharmaceuticals Ltd announces Quarter 1 FY 15 results

##### Highlights Qtr 1 FY 15

- Consolidated revenue at Rs 313.72 crs for Qtr1 FY 15 as against Rs 227.27 crs for Qtr1 FY 14 reflecting a sales growth of 38%.
- Adjusted for R&D expenses, the EBITDA for Qtr1 FY15 was Rs 29.66 crs against Rs 10.77 crs in Qtr1 FY 14 - EBITDA growth 175%.
- Company focus on formulations exports to regulated markets paying off with a 73% growth in formulation sales.
- Total R&D spend at Rs 8.66 crs out of which formulation development R&D spend Rs 4.79 crs (9.48% of formulation sales).
- 5 ANDAs for complex Formulation filed in this Qtr - with this total ANDAs filed is 15 and as of date 4 ANDA's approved.

##### Consolidated Financials:

- The consolidated gross revenue is Rs. 313.72 Crs. for Q1 FY 15 as compared to Rs. 227.27 Crs. for Q1 FY 14, a growth of 38%.
- The consolidated EBIDTA for Q1 FY 15 after R&D cost is Rs. 21.00 Crs. as against last year's Q1 FY 14 Rs. 7.23 Crs.
- During the current quarter, company has incurred loss of Rs. 4.80 Crs., mainly due to phasing of orders in UK operations, compared to Rs. 6.57 Crs. loss during last year Q1.

##### Standalone Financials:

- The standalone gross revenue is Rs. 250.39Crs. for Q1 FY 15 as compared to Rs. 175.95Crs. for Q1 FY 14, a growth of 42%.
- The standalone EBIDTA for Q1 FY 15 after R&D cost is Rs. 22.64Crs. as against last year's Q1 FY 14 Rs. 7.71Crs.
- During the current quarter, company earned a profit of Rs. 3.66 Crs compared to Rs. 2.51 Crs. in Q1 FY 14.

##### Formulations:

- Formulations sales for Q1 FY 15 is Rs. 50.54 Crs as compared to Rs. 29.17 Crs for Q1 FY 14, sales growth of 73%, mainly from sales in the regulated markets.

##### API:

- API sales for Q1 FY 15 is Rs. 176.19 Crs. as compared to Rs. 118.02 Crs in Q1 FY 14, growth of 49%.
- During this current quarter our API facility has successfully completed USFDA and COPPERIS inspection.

- 1 DMF has been filed in this quarter for the US market.

**SPSL UK:**

- CRAMS API sales for Q1 FY 15 is GBP. 6.21 mn compared to Q1 FY 14 GBP 5.92 mn.
- SPSL UK has incurred a net loss of GBP 0.76 mn during this current quarter, mainly due to sales phasing based on customer requirements.
- 10 new customers have been added and the portfolio of products has widened to ensure bigger contract manufacturing opportunities.
- For FY 15, SPSL UK shall achieve 15-20% growth over the last year sales and net profit will increase substantially compared to FY 14.

**Mr. S. Abhaya Kumar's comments on Q1 performance:**

*"I am pleased with the overall development of the business across sectors with a marked improvement in formulations. While the UK operations were subdued, I am confident that UK operations will revive in the near future and will deliver profit within the year."*

**About Shasun Pharmaceuticals Limited:**

Shasun Pharmaceuticals Ltd, listed on the Bombay Stock Exchange Limited (stock code: 524552) and the National Stock Exchange of India Limited (stock code: SHASUNPHAR) is an integrated pharmaceutical company head office in Chennai India with locations in India, UK and USA. For more information about Shasun Pharmaceuticals Ltd please visit [www.shasun.com](http://www.shasun.com).

**For further information please contact:**

**Shasun Pharmaceutical Limited**

Mr. S. Hariharan,

Chief Financial Officer

[hari@shasun.com](mailto:hari@shasun.com)

+91 98410 46299

**Safe Harbor**

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Shasun Pharmaceuticals Limited may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.